Table 5.

Assessment of associations between proteins plasma membrane expression and pathological data in CRC primary tumours

	MCT1			MCT4			CD147			GLUT1
	n	Positive (%)	p	n	Positive (%)	p	n	Positive (%)	p	n	Positive (%)	p
Tumor size (cm)
≤4.5	286	93.4	0.389	278	54.7	0.265	283	27.9	0.003	267	29.6	0.466
>4.5	182	91.2		175	60.0		180	41.1		167	26.3
Histological Type
Adenocarcinoma	417	92.8	0.456	402	57.0	0.862	411	33.6	0.787	386	28.2	0.389
A. Mucinous	51	90.2		49	57.1		52	28.8		46	26.1
A. Invasive	24	95.8		24	54.2		23	26.1		23	39.1
Signet ring and mucinous	4	75.0		3	33.3		4	25.0		4	0.0
Differentiation
Well-differentiated	219	93.2	0.271	213	56.8	0.070	217	34.6	0.875	202	21.3	0.009
Moderately-differentiated	209	93.3		204	55.4		206	32.5		197	35.0
Poorly-differentiated	49	85.7		43	69.8		48	29.2		43	39.5
Undifferentiated	4	100.0		3	0.0		4	25.0		3	33.3
Tumour Penetration
Tis	5	100.0	0.946	6	16.7	0.277	4	25.0	0.034	5	0.0	0.436
T1	30	90.0		28	50.0		30	13.3		27	29.6
T2	59	93.2		58	56.9		59	30.5		55	21.8
T3	376	92.6		359	57.7		371	33.2		350	29.4
T4	24	91.7		25	64.0		24	54.2		20	35.0
Spread to lymph nodes
Absent	280	92.5	0.888	272	54.0	0.269	277	32.5	0.876	263	25.5	0.058
Present	204	92.2		196	59.2		202	33.2		187	33.7
Vessel invasion
Absent	159	94.3	0.255	159	58.5	0.541	156	33.3	0.817	150	25.3	0.194
Present	314	91.4		299	55.5		313	32.3		291	31.3
TNM
Stage I	77	92.1	0.566	77	52.0	0.464	77	22.1	0.147	74	23.3	0.206
Stage II	183	92.9		179	57.0		181	36.5		173	26.0
Stage III	155	94.2		151	57.6		154	34.4		142	30.3
Stage IV	75	88.0		67	59.7		73	31.5		66	39.4
BRAF mutations
Negative	87	94.3	1.000	56	65.9	0.608	33	38.4	0.641	16	19.8	0.196
Positive (V600E)	4	100		2	50.0		2	50.0		2	50.0
KRAS mutations (codon12/13 and 61)
Negative	78	96.3	0.437	51	64.6	0.217	27	34.2	0.668	17	21.8	0.411
Positive	41	93.2		31	75.6		16	38.1		6	15.4
Microsatellite Instability
Negative	102	95.3	0.986	66	65.3	0.335	38	36.5	0.321	20	20.2	0.984
Positive (MSI-L + MSI-H)	20	95.2		16	76.2		5	25.0		4	20.0